Novel biallelic mutations in the DUOX2 gene underlying very early-onset inflammatory bowel disease: A case report

Clin Immunol. 2022 May:238:109015. doi: 10.1016/j.clim.2022.109015. Epub 2022 Apr 14.

Abstract

Genetic variants affecting the function of dual oxidase 2 (DUOX2), the catalytic subunit of membrane-bound enzymes that produce hydrogen peroxide, are associated with very early-onset inflammatory bowel disease (VEO-IBD). We report the case of a 1-year-old boy diagnosed with VEO-IBD after presenting with bloody diarrhea. He had pancolitis and an extensive small intestinal ulcerative lesion at age 4 years. Infliximab treatment was successful but was discontinued due to delayed reaction. At age 7 years, treatment with ustekinumab was started, and remission has been maintained for more than 2 years. Whole-exome sequencing identified compound heterozygous missense DUOX2 variants of unknown significance (p.[R1212H];[F1490Y]). Protein expression in the whole-cell lysate and plasma membrane was lower in F1490Y-DUOX2 than in wild-type (WT)-DUOX2. Hydrogen peroxide generation upon ionomycin stimulation was lower in cells expressing R1212H-DUOX2 and F1490Y-DUOX2 than in those expressing WT-DUOX2. The novel, inherited, biallelic DUOX2 mutations may be molecular risk factors of VEO-IBD.

Keywords: Crohn's disease; Dual oxidase 2; Inflammatory bowel disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Child, Preschool
  • Dual Oxidases / genetics
  • Humans
  • Hydrogen Peroxide*
  • Infant
  • Inflammatory Bowel Diseases* / genetics
  • Infliximab
  • Male
  • Mutation
  • NADPH Oxidases / genetics

Substances

  • Infliximab
  • Hydrogen Peroxide
  • Dual Oxidases
  • NADPH Oxidases
  • DUOX2 protein, human